Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 7:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 16,003 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting Phase 2 Interventional Results available

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

NCT03674411
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Biphenotypic/Undifferentiated Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Relapsed Large Cell Lymphoma, Mantle Cell Lymphoma, Hodgkin Lymphoma, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI), Tacrolimus (Tac), Mycophenolate Mofetil (MMF), Granulocyte Colony-Stimulating Factor (G-CSF), Busulfan (BU), Melphalan, MGTA 456 Infusion
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Domestic Violence
Interventions
NFP + IPV intervention
Behavioral
Lead sponsor
McMaster University
Other
Eligibility
16 Years and older · Female only
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Lymphangioleiomyomatosis, Lymphangiomyomas, Pleural Effusions, Ascites
Interventions
Octreotide
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 65 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), placebo, reusable pen device for insulin injection
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
12,537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Gastrointestinal Cancer, Rectal Cancer
Interventions
Procrit (epoetin alfa)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
1
States / cities
Houston, Texas
Conditions
Melanoma (Skin)
Interventions
MART-1 antigen, gp100 antigen
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
Boston, Massachusetts • Cambridge, Massachusetts • Houston, Texas
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
bortezomib, melphalan, pegylated liposomal doxorubicin hydrochloride
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Conditions
Tissue Plasminogen Activator, Intraventricular Brain Hemorrhage
Interventions
Tissue Plasminogen Activator (tPA), Isotonic solution
Drug · Procedure
Lead sponsor
David Dornbos
Other
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Sickle Cell Disease
Interventions
Fludarabine monophosphate, Rituximab, Busulfan, ATG, Cyclophosphamide, Mycophenolate mofetil, Tacrolimus
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Healthy Volunteers
Interventions
Avonex
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Breast Cancer
Interventions
GP2 peptide + GM-CSF vaccine, GM-CSF (sargramostim), AE37 + GM-CSF vaccine
Biological
Lead sponsor
San Antonio Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
11
States / cities
Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 7 more
Conditions
Glioblastoma, Recurrent Glioblastoma, GBM, Recurrent GBM
Interventions
Radiation: Intra-operative Radiation Therapy - IORT, Bevacizumab
Radiation · Drug
Lead sponsor
Xoft, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older · Male only
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
10
States / cities
Los Angeles, California • Stanford, California • Chicago, Illinois + 6 more
Conditions
Femoral Fracture, Fragility Fracture, Muscle Atrophy
Interventions
Essential Amino Acid Supplementation
Combination Product
Lead sponsor
Michael C Willey
Other
Eligibility
65 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Iowa City, Iowa • Eugene, Oregon
Conditions
Uveal Melanoma
Interventions
Melphalan through Percutaneous Hepatic Perfusion, Melphalan through Percutaneous Hepatic Perfusion in combination with Ipilimumab and Nivolumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cerebrovascular Accident
Interventions
Interferon beta-1a
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 85 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec, insulin glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
57
States / cities
Northridge, California • Palm Springs, California • Paramount, California + 53 more
Conditions
Essential Tremor
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine, Refresh Plus
Drug
Lead sponsor
Innovative Medical
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Greensboro, North Carolina
Conditions
Diabetes Mellitus, Type 2
Interventions
exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
60
States / cities
Birmingham, Alabama • Anaheim, California • Bellflower, California + 57 more
Conditions
Lymphoma
Interventions
rituximab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
7
States / cities
Duarte, California • Los Angeles, California • Washington D.C., District of Columbia + 2 more
Conditions
Advanced Melanoma
Interventions
Ipilimumab, Carboplatin, Paclitaxel, Dacarbazine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Tampa, Florida • New York, New York + 1 more
Conditions
Fertility
Interventions
Bravelle and Menopur, Agonist, Antagonist
Drug
Lead sponsor
Main Line Fertility Center
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Conditions
Chronic Rhinosinusitis With Nasal Polyps, Asthma
Interventions
Dupilumab, Omalizumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Los Angeles, California • Tampa, Florida • Chicago, Illinois + 12 more